Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Veniti Inc.

Division of Boston Scientific Corp.
www.veniti.com

Latest From Veniti Inc.

FDA Approves Boston Scientific’s Vici Venous Iliac Stent

The US FDA approval of Boston Scientific's Vici venous stent is based on VIRTUS trial results which met the prespecified performance goal for primary patency after one year.

Approvals Clinical Trials

Boston Scientific Buys Venous Stent-Developer Veniti For $160M

Boston Scientific has agreed to pay up to $160m for the remaining 75% of Veniti Inc. that it does not already own. Veniti is a privately held Fremont, Calif. company that has developed and commercialized the Vici venous stent system for treating venous obstructive disease. The transaction price includes $108m upfront and $52m contingent on US FDA approval of Vici.

M & A Deals

Device/Diagnostics Quarterly Deal Statistics, Q3 2016

Q3 medtech financing doubled in dollar volume to $3 billion, with debt offerings again representing the majority of the aggregate; acquisitions totaled $5.3 billion, mainly due to Johnson & Johnson’s $4.3 billion buy of Abbott Medical Optics. Diagnostics financings, which brought in $85 million, continued to decline, but at $5 billion, acquisitions showed a slight increase over the previous quarter, with Danaher’s takeover of Cepheid accounting for most of the M&A volume.

Market Intelligence Deals

Venture Funding Deals, April 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced February through March 2015.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Boston Scientific Corp.
  • Senior Management
  • Jeff Elkins, Pres. & CEO
    Catherine Matthes, CFO
    Rodney Marcy, Chief Commercialization Officer
  • Contact Info
  • Veniti Inc.
    Phone: (314) 282-3753
    4025 Clipper Court
    Fremont, CA 94538
    USA
UsernamePublicRestriction

Register